Estado epiléptico refractario y superrefractario en el adulto: certeza, consistencia y validez externa de la evidencia disponible
Salud Medicina e Innovación Journal · 06.08.2026 · 4 (3) · 319-343
DOI: 10.70577/atxhqv93 ↗Kurz gefasst
Fachartikel in der Zeitschrift Salud Medicina e Innovación Journal, online erschienen am 06.08.2026. Verfasst von Jimmy Yaguana Torres und 4 weiteren Autor:innen. Die Arbeit nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-SA 4.0).
Abstract (Originalsprache)
Although used in clinical practice for decades, most third-line therapies for refractory and super-refractory status epilepticus remain supported primarily by observational studies. In this field, the main issue is no longer a lack of therapeutic alternatives, but rather the low certainty and limited external validity of the available evidence. The objective was to critically analyze the certainty, consistency, and external validity of the evidence supporting current diagnostic and therapeutic strategies for refractory status epilepticus (RSE) and super-refractory status epilepticus (SRSE) in adults, as well as their applicability in centers lacking continuous electroencephalographic monitoring or access to immunotherapy. A narrative review was conducted using a structured and reproducible search strategy across PubMed/MEDLINE, Scopus, and Web of Science, with the final search performed on July 31, 2026. Search strings, eligibility criteria, and the qualitative framework used to assess the certainty of the evidence are detailed. Priority was given to randomized trials, systematic reviews, formal consensus documents, and cohorts with multivariable adjustment. The most robust evidence is limited to first- and second-line treatment: the three second-line antiseizure medications show comparable efficacy, although approximately half of the patients do not respond to the drug administered despite receiving a full dose. External validation of the Salzburg criteria shows lower diagnostic performance than in the derivation cohort, warranting caution before inducing anesthetic coma. No third-line intervention is supported by moderate- or high-certainty evidence demonstrating improved outcomes. For cryptogenic NORSE and FIRES, the most relevant practical recommendation is to initiate first-line immunotherapy within the first 72 hours. The current therapeutic algorithm assumes the availability of continuous electroencephalographic monitoring and immunotherapy, yet its external validity in centers lacking these resources has not been evaluated. The best-supported modifiable intervention remains the early and adequately dosed administration of first- and second-line treatments.
Zitieren
APA
Torres, J. Y., Guillen, H. F., Leyton, H. J. B., Sánchez, P. A. A., & Orrala, F. E. C. (2026). Estado epiléptico refractario y superrefractario en el adulto: certeza, consistencia y validez externa de la evidencia disponible. Salud Medicina e Innovación Journal, 4(3), 319-343. https://doi.org/10.70577/atxhqv93
Vancouver
Torres JY, Guillen HF, Leyton HJB, Sánchez PAA, Orrala FEC. Estado epiléptico refractario y superrefractario en el adulto: certeza, consistencia y validez externa de la evidencia disponible. Salud Medicina e Innovación Journal. 2026;4(3):319-343. doi:10.70577/atxhqv93
BibTeX
@article{Torres2026,
author = {Torres, Jimmy Yaguana and Guillen, Henry Friman and Leyton, Hugo Joseph Behr and Sánchez, Pedro Andrés Agila and Orrala, Freddy Eduardo Chalén},
title = {Estado epiléptico refractario y superrefractario en el adulto: certeza, consistencia y validez externa de la evidencia disponible},
journal = {Salud Medicina e Innovación Journal},
year = {2026},
volume = {4},
number = {3},
pages = {319--343},
doi = {10.70577/atxhqv93}
}
EUVIMED